Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 4c

Aurinia Reports Second Quarter Financial Results and Operational Highlights

August 9, 2018 4:03 PM EDT

AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule

Trials in FSGS and Dry Eye initiated

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (Aurinia or the Company) has released its financial results for the second quarter ended June 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.

We are excited to announce that the AURORA Phase III trial in lupus nephritis is running ahead of schedule and we now anticipate completing enrollment in... More